secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clene Inc. (CLNN)
CIK:        0001822791
Form:       8-K
Filed at:   2023-03-13T23:59:59+00:00
Accession:  0001437749-23-006270
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clene reports FY2022 net loss of $29.9M; highlights positive clinical data in ALS and MS
--------------------------------------------------------------------------------

- Net loss $29.9M ($0.46/share) vs $9.7M ($0.16) prior year; cash $23.3M, runway into Q3 2023.
- HEALEY ALS trial: CNM-Au8 associated with 74% lower risk of clinical worsening at 6 months; 98% reduced risk of death/permanent ventilation.
- RESCUE-ALS OLE: significant ALSFRS-R preservation from randomization to 48 weeks (p=0.0159).
- VISIONARY-MS trial: significant improvements in visual evoked potential and MRI measures supporting neuroprotection.
- Plans to meet FDA in Q3 2023 for end-of-Phase 2 meetings for ALS and MS; secured $25M equity facility with Lincoln Park.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822791/000143774923006270/0001437749-23-006270-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822791/000143774923006270/clnn20221214_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-006270

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer